JP2015509522A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509522A5 JP2015509522A5 JP2014560382A JP2014560382A JP2015509522A5 JP 2015509522 A5 JP2015509522 A5 JP 2015509522A5 JP 2014560382 A JP2014560382 A JP 2014560382A JP 2014560382 A JP2014560382 A JP 2014560382A JP 2015509522 A5 JP2015509522 A5 JP 2015509522A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- motomeko
- toxoid
- composition
- tlr agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 59
- 239000000556 agonist Substances 0.000 claims description 22
- 102000002689 Toll-like receptor Human genes 0.000 claims description 20
- 108020000411 Toll-like receptor Proteins 0.000 claims description 20
- 201000005702 Pertussis Diseases 0.000 claims description 14
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 12
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 12
- 229960000814 tetanus toxoid Drugs 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 8
- 230000002163 immunogen Effects 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 4
- 108010021711 pertactin Proteins 0.000 claims description 4
- 238000001179 sorption measurement Methods 0.000 claims description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 2
- 229940032024 DPT vaccine Drugs 0.000 claims description 2
- 241000991587 Enterovirus C Species 0.000 claims description 2
- 101710154606 Hemagglutinin Proteins 0.000 claims description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 101710176177 Protein A56 Proteins 0.000 claims description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000185 hemagglutinin Substances 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 239000007764 o/w emulsion Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 229940068968 polysorbate 80 Drugs 0.000 claims description 2
- 229940031439 squalene Drugs 0.000 claims description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 2
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261608398P | 2012-03-08 | 2012-03-08 | |
| US61/608,398 | 2012-03-08 | ||
| US201261697730P | 2012-09-06 | 2012-09-06 | |
| US61/697,730 | 2012-09-06 | ||
| PCT/EP2013/054672 WO2013132041A2 (en) | 2012-03-08 | 2013-03-08 | Adjuvanted formulations of booster vaccines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017096343A Division JP2017132821A (ja) | 2012-03-08 | 2017-05-15 | 追加免疫ワクチンのアジュバント化された処方物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015509522A JP2015509522A (ja) | 2015-03-30 |
| JP2015509522A5 true JP2015509522A5 (https=) | 2016-04-21 |
| JP6345603B2 JP6345603B2 (ja) | 2018-06-20 |
Family
ID=47843287
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014560382A Active JP6345603B2 (ja) | 2012-03-08 | 2013-03-08 | 追加免疫ワクチンのアジュバント化された処方物 |
| JP2017096343A Withdrawn JP2017132821A (ja) | 2012-03-08 | 2017-05-15 | 追加免疫ワクチンのアジュバント化された処方物 |
| JP2018194314A Pending JP2019001832A (ja) | 2012-03-08 | 2018-10-15 | 追加免疫ワクチンのアジュバント化された処方物 |
| JP2021015094A Active JP7295895B2 (ja) | 2012-03-08 | 2021-02-02 | 追加免疫ワクチンのアジュバント化された処方物 |
| JP2023045185A Pending JP2023085364A (ja) | 2012-03-08 | 2023-03-22 | 追加免疫ワクチンのアジュバント化された処方物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017096343A Withdrawn JP2017132821A (ja) | 2012-03-08 | 2017-05-15 | 追加免疫ワクチンのアジュバント化された処方物 |
| JP2018194314A Pending JP2019001832A (ja) | 2012-03-08 | 2018-10-15 | 追加免疫ワクチンのアジュバント化された処方物 |
| JP2021015094A Active JP7295895B2 (ja) | 2012-03-08 | 2021-02-02 | 追加免疫ワクチンのアジュバント化された処方物 |
| JP2023045185A Pending JP2023085364A (ja) | 2012-03-08 | 2023-03-22 | 追加免疫ワクチンのアジュバント化された処方物 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9375471B2 (https=) |
| EP (1) | EP2822581A2 (https=) |
| JP (5) | JP6345603B2 (https=) |
| CN (1) | CN104159602B (https=) |
| AU (1) | AU2013229432A1 (https=) |
| CA (1) | CA2866406A1 (https=) |
| MX (1) | MX372965B (https=) |
| RU (1) | RU2014140521A (https=) |
| WO (1) | WO2013132041A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2467108T3 (es) | 2008-12-09 | 2014-06-11 | Gilead Sciences, Inc. | Moduladores de receptores tipo toll |
| GB0822633D0 (en) * | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
| ES2443952T3 (es) * | 2009-09-02 | 2014-02-21 | Novartis Ag | Composiciones inmunógenas que incluyen moduladores de la actividad de TLR |
| ES2458355T3 (es) | 2010-09-01 | 2014-05-05 | Novartis Ag | Adsorción de inmunopotenciadores sobre sales metálicas insolubles |
| WO2012117377A1 (en) * | 2011-03-02 | 2012-09-07 | Novartis Ag | Combination vaccines with lower doses of antigen and/or adjuvant |
| SG11201400210RA (en) * | 2011-09-01 | 2014-03-28 | Novartis Ag | Adjuvanted formulations of staphylococcus aureus antigens |
| MX372965B (es) * | 2012-03-08 | 2020-04-01 | Glaxosmithkline Biologicals Sa | Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo. |
| US9149522B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US20150086592A1 (en) | 2013-09-25 | 2015-03-26 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9149521B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9504743B2 (en) | 2013-09-25 | 2016-11-29 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| BE1022857A1 (fr) | 2014-03-26 | 2016-09-27 | Glaxosmithkline Biologicals Sa | Immunisation contre staphylococcus aureus |
| PT3166607T (pt) | 2014-07-11 | 2022-12-07 | Gilead Sciences Inc | Moduladores de receptores de tipo toll para o tratamento do vih |
| CA2960436C (en) | 2014-09-16 | 2021-01-05 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
| DK3458475T3 (da) * | 2016-05-16 | 2022-09-12 | Access To Advanced Health Inst | Formulering, der indeholder tlr-agonist, og anvendelsesfremgangsmåder |
| US20220054615A1 (en) * | 2018-12-05 | 2022-02-24 | Sanofi Pasteur Inc. | Pertussis booster vaccine |
| WO2025240361A1 (en) * | 2024-05-13 | 2025-11-20 | The Board Of Trustees Of The Leland Stanford Junior University | Enpp1 and/or enpp3 inhibitors |
| US12605349B2 (en) | 2024-09-05 | 2026-04-21 | Orbus Therapeutics, Inc. | Methods of treating grade 3 astrocytoma |
Family Cites Families (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3485094D1 (de) | 1983-01-25 | 1991-10-31 | Ciba Geigy Ag | Neue peptidderivate. |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US5059258A (en) | 1989-08-23 | 1991-10-22 | Aluminum Company Of America | Phosphonic/phosphinic acid bonded to aluminum hydroxide layer |
| IT1248735B (it) * | 1990-06-21 | 1995-01-26 | Sclavo Spa | Vaccini acellulari contro la pertosse |
| US6699474B1 (en) | 1990-08-20 | 2004-03-02 | Erich Hugo Cerny | Vaccine and immunserum against drugs of abuse |
| US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
| DE69333110T2 (de) | 1992-03-02 | 2004-05-06 | Chiron S.P.A. | Mit dem cytotoxin von helicobacter pylori assoziiertes, immunodominantes antigen verwendbar in impfstoffen und zur diagnose |
| ATE157882T1 (de) | 1993-03-23 | 1997-09-15 | Smithkline Beecham Biolog | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
| WO1995011700A1 (en) | 1993-10-29 | 1995-05-04 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
| FR2718452B1 (fr) | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
| JPH10502365A (ja) | 1994-07-01 | 1998-03-03 | リカン・リミテッド | ヘリコバクタータンパク質およびワクチン |
| ES2193205T3 (es) | 1994-11-24 | 2003-11-01 | Basilea Pharmaceutica Ag | Nuevas bencil pirimidinas. |
| WO1997025429A1 (en) | 1996-01-04 | 1997-07-17 | Rican Limited | Helicobacter pylori bacterioferritin |
| GB9623233D0 (en) * | 1996-11-07 | 1997-01-08 | Smithkline Beecham Biolog | Vaccine composition |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| HK1039072A1 (zh) | 1998-05-07 | 2002-04-12 | 科里克萨有限公司 | 佐剂组合物及其使用方法 |
| GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
| US20030130212A1 (en) | 1999-01-14 | 2003-07-10 | Rossignol Daniel P. | Administration of an anti-endotoxin drug by intravenous infusion |
| US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
| DE10012370A1 (de) * | 2000-03-14 | 2001-09-27 | Chiron Behring Gmbh & Co | Adjuvans für Vakzinen |
| GB0108364D0 (en) * | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
| WO2002002606A2 (en) | 2000-07-03 | 2002-01-10 | Chiron S.P.A. | Immunisation against chlamydia pneumoniae |
| FR2827605B1 (fr) | 2001-07-20 | 2004-07-16 | Pf Medicament | Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin |
| CN100515494C (zh) | 2001-12-12 | 2009-07-22 | 启龙有限公司 | 抗沙眼衣原体的免疫 |
| GB0211118D0 (en) | 2002-05-15 | 2002-06-26 | Polonelli Luciano | Vaccines |
| WO2003105769A2 (en) | 2002-06-13 | 2003-12-24 | New York University | Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
| HUE031886T2 (en) | 2002-10-11 | 2017-08-28 | Glaxosmithkline Biologicals Sa | Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines |
| US7818252B2 (en) | 2003-02-20 | 2010-10-19 | Gilat Satellite Networks, Ltd | Enforcement of network service level agreements |
| DE602004031115D1 (de) | 2003-06-16 | 2011-03-03 | Acad Of Science Czech Republic | Pyrimidinverbindungen mit phosphonatgruppen als antivirale nucleotidanaloga |
| CN1812809A (zh) | 2003-06-26 | 2006-08-02 | 希龙公司 | 用于沙眼衣原体的免疫原性组合物 |
| US7771726B2 (en) | 2003-10-08 | 2010-08-10 | New York University | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases |
| CA2557353A1 (en) | 2004-03-02 | 2005-09-15 | Chiron Corporation | Immunogenic compositions for chlamydia pneunomiae |
| GB0405787D0 (en) | 2004-03-15 | 2004-04-21 | Chiron Srl | Low dose vaccines |
| CN1964626A (zh) | 2004-03-31 | 2007-05-16 | 纽约大学 | 新型合成c－糖脂、其合成及其治疗传染病、癌症和自身免疫性疾病的用途 |
| AU2005230708B2 (en) | 2004-04-05 | 2009-01-15 | Zoetis Services Llc | Microfluidized oil-in-water emulsions and vaccine compositions |
| NZ599345A (en) | 2005-02-18 | 2013-07-26 | Novartis Vaccines & Diagnostic | Immunogens from uropathogenic Escherichia Coli |
| AU2006214064B2 (en) | 2005-02-18 | 2012-04-26 | J. Craig Venter Institute, Inc. | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
| EP1866319B1 (en) | 2005-04-01 | 2011-11-23 | The Regents of The University of California | Phosphono-pent-2-en-1-yl nucleosides and analogs |
| EP1891096A2 (en) | 2005-05-12 | 2008-02-27 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions for chlamydia trachomatis |
| US8398983B2 (en) | 2005-06-27 | 2013-03-19 | Glaxosmithkline Biologicals, S.A. | Immunogenic composition |
| US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
| TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯 |
| TW200801003A (en) | 2005-09-16 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
| JPWO2007034881A1 (ja) | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
| TW200745114A (en) | 2005-09-22 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| EP1939202A4 (en) | 2005-09-22 | 2010-06-16 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
| WO2007034917A1 (ja) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規なアデニン化合物 |
| EP1939200A4 (en) | 2005-09-22 | 2010-06-16 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
| AR056591A1 (es) | 2005-10-28 | 2007-10-10 | Vaxinnate Corp | Polipeptidos ligandos para receptor 4 simil toll (tlr4) |
| EP1951298A1 (en) | 2005-11-04 | 2008-08-06 | Novartis Vaccines and Diagnostics S.r.l. | Adjuvanted influenza vaccines including cytokine-inducing agents |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| AU2006341122B2 (en) | 2005-12-22 | 2013-08-22 | Novartis Vaccines And Diagnostics, Srl. | Chlamydial antigens |
| FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
| WO2007093901A1 (en) | 2006-02-17 | 2007-08-23 | Pfizer Limited | 3 -deazapurine derivatives as tlr7 modulators |
| CA2646539A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| CA2646891A1 (en) * | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| EP2041135A4 (en) | 2006-07-05 | 2010-12-01 | Astrazeneca Ab | As TLR7 MODULATORS, 8-OXOADENINE DERIVATIVES WORK |
| EP2038290B1 (en) | 2006-07-07 | 2013-09-04 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
| GB0616306D0 (en) | 2006-08-16 | 2006-09-27 | Novartis Ag | Vaccines |
| WO2008020330A2 (en) | 2006-08-16 | 2008-02-21 | Novartis Ag | Immunogens from uropathogenic escherichia coli |
| US8945582B2 (en) | 2006-09-07 | 2015-02-03 | Glaxosmithkline Biologicals S.A. | Vaccine |
| KR101151202B1 (ko) | 2006-10-12 | 2012-06-11 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 수중유 에멀젼 애주번트를 포함하는 백신 |
| WO2008047174A1 (en) | 2006-10-18 | 2008-04-24 | Centre National De La Recherche Scientifique | Alpha-galactosylceramide analogs, their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them |
| GB0622282D0 (en) | 2006-11-08 | 2006-12-20 | Novartis Ag | Quality control methods |
| US20100120799A1 (en) | 2007-02-19 | 2010-05-13 | Smithkline Beecham Corporation | Purine derivatives as immunomodulators |
| AR065784A1 (es) | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
| KR20100016289A (ko) | 2007-05-08 | 2010-02-12 | 아스트라제네카 아베 | 면역-조정 특성의 이미다조퀴놀린 |
| CA2688268A1 (en) * | 2007-06-04 | 2008-12-11 | Novartis Ag | Formulation of meningitis vaccines |
| CA2707030A1 (en) | 2007-08-03 | 2009-02-12 | Pfizer Limited | Imidazopyridinones |
| WO2009050586A1 (en) | 2007-10-19 | 2009-04-23 | Novartis Ag | Meningococcal vaccine formulations |
| PE20091236A1 (es) | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
| AU2008339631B2 (en) | 2007-12-24 | 2014-07-24 | Novartis Ag | Assays for adsorbed influenza vaccines |
| US8092813B1 (en) | 2007-12-28 | 2012-01-10 | Novartis Ag | Polychlorinated biphenyls and squalene-containing adjuvants |
| PT2268618E (pt) | 2008-03-03 | 2015-10-12 | Novartis Ag | Compostos e composições moduladores da actividade tlr |
| ES2667054T3 (es) | 2008-03-24 | 2018-05-09 | Biontech Ag | Nuevas imidazoquinolinas sustituidas |
| WO2010003009A2 (en) | 2008-07-01 | 2010-01-07 | Emory University | Synergistic induction of humoral and cellular immunity by combinatorial activation of toll-like receptors |
| WO2010014913A1 (en) | 2008-08-01 | 2010-02-04 | Ventirx Pharmaceuticals, Inc. | Toll-like receptor agonist formulations and their use |
| RS51999B (sr) | 2008-08-28 | 2012-04-30 | Novartis Ag | Dobijanje skvalena iz hiperprodukcijskih kvasaca |
| TWM352127U (en) | 2008-08-29 | 2009-03-01 | Bestac Advanced Material Co Ltd | Polishing pad |
| ES2467108T3 (es) | 2008-12-09 | 2014-06-11 | Gilead Sciences, Inc. | Moduladores de receptores tipo toll |
| GB0822633D0 (en) * | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
| AR075437A1 (es) | 2009-02-17 | 2011-03-30 | Glaxosmithkline Biolog Sa | Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio, metodo para producir dicha vacuna y su uso para preparar un medicamento |
| MX2011010735A (es) | 2009-04-14 | 2012-01-25 | Novartis Ag | Composiciones para inmunizacion contra staphylococcus aureus. |
| RU2011154363A (ru) | 2009-06-01 | 2013-07-20 | Новартис Аг | Комбинации клад rrgb пневмококков |
| CA2765112A1 (en) | 2009-06-10 | 2010-12-16 | Novartis Ag | Benzonaphthyridine-containing vaccines |
| US20110076300A1 (en) | 2009-08-27 | 2011-03-31 | Mariagrazia Pizza | Hybrid Polypeptides Including Meningococcal fHBP Sequences |
| ES2443952T3 (es) | 2009-09-02 | 2014-02-21 | Novartis Ag | Composiciones inmunógenas que incluyen moduladores de la actividad de TLR |
| JO3257B1 (ar) * | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
| EP2498815A4 (en) | 2009-11-09 | 2014-03-19 | Nat Jewish Health | VACCINE COMPOSITION |
| JP5751678B2 (ja) | 2009-12-03 | 2015-07-22 | ノバルティス アーゲー | マイクロフルイダイゼーションのための相互作用チャンバおよび背圧チャンバの構成 |
| RS52748B (sr) | 2009-12-03 | 2013-08-30 | Novartis Ag | Cirkulacija komponenti tokom homogenizacije emulzija |
| EP2506832B1 (en) | 2009-12-03 | 2014-02-26 | Novartis AG | Hydrophilic filtration during manufacture of vaccine adjuvants |
| AU2011232421B2 (en) | 2010-03-23 | 2015-08-13 | Novartis Ag | Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc. |
| WO2011130379A1 (en) | 2010-04-13 | 2011-10-20 | Novartis Ag | Benzonapthyridine compositions and uses thereof |
| SG185419A1 (en) | 2010-05-12 | 2012-12-28 | Novartis Ag | Improved methods for preparing squalene |
| GB201009676D0 (en) | 2010-06-10 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel process |
| GB201009673D0 (en) | 2010-06-10 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel process |
| GB201009671D0 (en) | 2010-06-10 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel process |
| ES2458355T3 (es) | 2010-09-01 | 2014-05-05 | Novartis Ag | Adsorción de inmunopotenciadores sobre sales metálicas insolubles |
| US9618508B2 (en) | 2010-12-14 | 2017-04-11 | Glaxosmithkline Biologicals Sa | Flow cytometry analysis of materials adsorbed to metal salts |
| WO2012117377A1 (en) | 2011-03-02 | 2012-09-07 | Novartis Ag | Combination vaccines with lower doses of antigen and/or adjuvant |
| SG11201400210RA (en) | 2011-09-01 | 2014-03-28 | Novartis Ag | Adjuvanted formulations of staphylococcus aureus antigens |
| JP2015510872A (ja) | 2012-03-07 | 2015-04-13 | ノバルティス アーゲー | Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤 |
| MX346678B (es) | 2012-03-07 | 2017-03-29 | Novartis Ag | Sales de arginina utiles inmunologicamente. |
| AU2013229465A1 (en) | 2012-03-07 | 2014-09-04 | Novartis Ag | Adjuvanted formulations of rabies virus immunogens |
| MX372965B (es) | 2012-03-08 | 2020-04-01 | Glaxosmithkline Biologicals Sa | Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo. |
| US9526776B2 (en) | 2012-09-06 | 2016-12-27 | Glaxosmithkline Biologicals Sa | Combination vaccines with serogroup B meningococcus and D/T/P |
| MX2015005306A (es) | 2012-10-25 | 2015-07-17 | Glaxosmithkline Biolog Sa | Nicotinamida como adyuvante. |
-
2013
- 2013-03-08 MX MX2014010417A patent/MX372965B/es active IP Right Grant
- 2013-03-08 CA CA2866406A patent/CA2866406A1/en not_active Abandoned
- 2013-03-08 JP JP2014560382A patent/JP6345603B2/ja active Active
- 2013-03-08 CN CN201380012817.4A patent/CN104159602B/zh active Active
- 2013-03-08 EP EP13708155.0A patent/EP2822581A2/en not_active Withdrawn
- 2013-03-08 US US13/790,948 patent/US9375471B2/en active Active
- 2013-03-08 AU AU2013229432A patent/AU2013229432A1/en not_active Abandoned
- 2013-03-08 RU RU2014140521A patent/RU2014140521A/ru not_active Application Discontinuation
- 2013-03-08 WO PCT/EP2013/054672 patent/WO2013132041A2/en not_active Ceased
-
2016
- 2016-05-24 US US15/163,592 patent/US9931399B2/en active Active
-
2017
- 2017-05-15 JP JP2017096343A patent/JP2017132821A/ja not_active Withdrawn
-
2018
- 2018-02-26 US US15/905,483 patent/US10842868B2/en active Active
- 2018-10-15 JP JP2018194314A patent/JP2019001832A/ja active Pending
-
2021
- 2021-02-02 JP JP2021015094A patent/JP7295895B2/ja active Active
-
2023
- 2023-03-22 JP JP2023045185A patent/JP2023085364A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015509522A5 (https=) | ||
| RU2014140521A (ru) | Адъювантные составы бустерных вакцин | |
| JP2014506916A5 (https=) | ||
| JP2014525429A5 (https=) | ||
| Shah et al. | Overview of vaccine adjuvants: introduction, history, and current status | |
| JP6110845B2 (ja) | 耐熱性ワクチン組成物及びそれを調製する方法 | |
| CN111212846B (zh) | 三萜皂苷类似物 | |
| US10188733B2 (en) | Vaccines comprising bisphosphonate and methods of use thereof | |
| Kocourkova et al. | Vaccine ingredients: components that influence vaccine efficacy | |
| Hawken et al. | Adjuvants and inactivated polio vaccine: a systematic review | |
| HRP20230359T1 (hr) | Imunogeni pripravak | |
| RU2013144207A (ru) | Комбинированные вакцины с пониженными дозами антигена и/или адъюванта | |
| JP2015028032A (ja) | ワクチン | |
| JPWO2020022272A5 (https=) | ||
| RU2008123006A (ru) | Получение вакцин, содержащих поверхностный антиген вируса гепатита в и поверхностно-активное вещество | |
| JP2018500322A5 (https=) | ||
| RU2015106745A (ru) | Иммуногенные композиции | |
| Mallet et al. | A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety | |
| WO2020118159A1 (en) | Methods and compositions comprising an nfkb inhibitor and an adjuvant | |
| JP2015509963A5 (https=) | ||
| AU2019376832B2 (en) | Immunogenic compositions | |
| JP2017509713A5 (https=) | ||
| RU2016141621A (ru) | Способы усиления эффективности иммуностимуляции адсорбированных на соли алюминия вакцин | |
| KR20150020164A (ko) | 보강제 제형 및 방법 | |
| JP5846624B2 (ja) | Ｈ５ｎ１型インフルエンザワクチン及び感染防御キット |